Deguelin, a Novel Anti-Tumorigenic Agent in Human Esophageal Squamous Cell Carcinoma

EBioMedicine. 2017 Dec:26:10. doi: 10.1016/j.ebiom.2017.11.010. Epub 2017 Nov 16.

Authors

Yuh Baba¹, Yasumasa Kato²

Affiliations

¹ Department of General Clinical Medicine, Ohu University School of Dentistry, 31-1 Mitsumido, Tomiya-machi, Koriyama City, Fukushima 963-8611, Japan. Electronic address: y-baba@den.ohu-u.ac.jp.
² Department of Oral Function and Molecular Biology, Ohu University School of Dentistry, 31-1 Mitsumido, Tomiya-machi, Koriyama City, Fukushima 963-8611, Japan.

No abstract available

Keywords: Anti-tumorigenic agent; Deguelin; Esophageal squamous cell carcinoma.

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Apoptosis / drug effects
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / mortality
Carcinoma, Squamous Cell / pathology
Cell Line, Tumor
Cetuximab / therapeutic use
Drug Therapy, Combination
Esophageal Neoplasms / drug therapy*
Esophageal Neoplasms / mortality
Esophageal Neoplasms / pathology
Esophageal Squamous Cell Carcinoma
G1 Phase Cell Cycle Checkpoints / drug effects
Humans
Rotenone / analogs & derivatives*
Rotenone / pharmacology
Rotenone / therapeutic use
Survival Rate

Substances

Antineoplastic Agents
Rotenone
deguelin
Cetuximab